TISIDB

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein.
Domain	PF08516 ADAM cysteine-rich PF00200 Disintegrin PF01562 Reprolysin family propeptide PF01421 Reprolysin (M12B) family zinc metalloprotease
Function	Sperm surface membrane protein that may be involved in sperm-egg plasma membrane adhesion and fusion during fertilization. Could have a direct role in sperm-zona binding or migration of sperm from the uterus into the oviduct. Interactions with egg membrane could be mediated via binding between its disintegrin-like domain to one or more integrins receptors on the egg. This is a non catalytic metalloprotease-like protein.

> Gene Ontology [ TOP ]
Biological Process	GO:0007338 single fertilization GO:0007339 binding of sperm to zona pellucida GO:0007342 fusion of sperm to egg plasma membrane GO:0007611 learning or memory GO:0007612 learning GO:0007632 visual behavior GO:0008037 cell recognition GO:0008306 associative learning GO:0008542 visual learning GO:0009314 response to radiation GO:0009416 response to light stimulus GO:0009566 fertilization GO:0009988 cell-cell recognition GO:0022412 cellular process involved in reproduction in multicellular organism GO:0030534 adult behavior GO:0035036 sperm-egg recognition GO:0044708 single-organism behavior GO:0044801 single-organism membrane fusion GO:0045026 plasma membrane fusion GO:0050890 cognition GO:0061025 membrane fusion
Molecular Function	GO:0004175 endopeptidase activity GO:0004222 metalloendopeptidase activity GO:0005178 integrin binding GO:0008237 metallopeptidase activity GO:0050839 cell adhesion molecule binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1187000: Fertilization R-HSA-1300644: Interaction With The Zona Pellucida R-HSA-1474165: Reproduction

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ADAM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ADAM2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ADAM2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.139	0.858
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.174	0.888
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.113	0.93
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.18	0.697
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.18	0.791
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.814	0.0113

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ADAM2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	22.2	12.3	9.9	0.224
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	22.2	13.6	8.6	0.353
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	19	23.5	-4.5	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	16.7	8.3	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	27.3	-11.9	0.63
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADAM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADAM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADAM2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADAM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ADAM2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ADAM2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ADAM2
Name	ADAM metallopeptidase domain 2
Aliases	PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location	8p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ADAM2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ADAM2